{
    "nct_id": "NCT03698370",
    "official_title": "68Ga-NeoBOMB1 and 68Ga-PSMA R2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer",
    "inclusion_criteria": "* Biopsy proven prostate adenocarcinoma.\n* Rising prostate-specific antigen (PSA) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy).\n\n  a. Post radical prostatectomy (RP) - American Urological Association (AUA) recommendation.\n\n  (i) PSA greater than 0.2 ng/mL measured after at least 6 weeks from radical prostatectomy.\n\n(ii) Confirmatory persistent PSA greater than 0.2 ng/mL (total of two PSA measurements greater than 0.2 ng/mL).\n\nb. Post-radiation therapy ? American Society for Therapeutic Radiology and Oncology (ASTRO)-Phoenix consensus definition.\n\n(i) A rise of PSA measurement of 2 or more ng/mL over the nadir.\n\n* Able to provide written consent.\n* Karnofsky performance status of >= 50 (or Eastern Cooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent).\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Inability to lie still for the entire imaging time.\n* Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.).\n* Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance.\n* Known allergy, hypersensitivity, or intolerance to the investigational product or its excipients.\n* Metallic implants (contraindicated for magnetic resonance imaging [MRI]).",
    "miscellaneous_criteria": ""
}